Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Jordan Berlin

10 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCGI15122

    01/15/2016

    Research Use of Human Biospecimens from Colorectal Cancer Patients (Pilot Study)

    Treatment

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Treatment

    VICCPHI1682

    11/17/2016

    An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013 (Pan-HER), a Monoclonal Antibody Mixture Targeting EGFR, HER2 and HER3, in Patients with Advanced Epithelial Malignancies

    Treatment

    VICCPHI1616

    06/08/2016

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    VICCGI1515

    01/05/2016

    A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCPHI1436

    08/18/2014

    A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors


    Print this page for your doctor